22nd Century Group (NASDAQ:XXII) Stock Crosses Below Fifty Day Moving Average – Here’s What Happened

22nd Century Group, Inc (NASDAQ:XXII)’s share price crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $3.03 and traded as low as $1.26. 22nd Century Group shares last traded at $1.37, with a volume of 60,619,066 shares traded.

22nd Century Group Trading Down 12.2%

The firm has a market capitalization of $986,400.00, a PE ratio of 0.00 and a beta of 0.77. The company’s 50-day moving average price is $3.03 and its 200-day moving average price is $10.40. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.83 and a current ratio of 2.42.

Institutional Investors Weigh In On 22nd Century Group

An institutional investor recently raised its position in 22nd Century Group stock. Anson Funds Management LP lifted its position in shares of 22nd Century Group, Inc (NASDAQ:XXII) by 677.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 763,212 shares of the biotechnology company’s stock after purchasing an additional 665,000 shares during the period. Anson Funds Management LP owned about 149.65% of 22nd Century Group worth $588,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 18.06% of the company’s stock.

22nd Century Group Company Profile

22nd Century Group, Inc, founded in 1998 and headquartered in New York, is a plant biotechnology company that applies proprietary breeding and gene modulation technologies to tobacco, hemp and related plant species. The company’s core mission is to develop and commercialize plant-based solutions that address public health, consumer wellness and agronomic needs. Its flagship reduced nicotine tobacco platform is engineered to deliver significantly lower levels of nicotine than conventional tobacco products while retaining the sensory characteristics sought by adult smokers.

Through its branded reduced nicotine tobacco products, marketed under the NEXT Generation™ portfolio, and its GenCanna® subsidiary focused on hemp cultivation and cannabinoid extraction, 22nd Century serves both commercial markets and contract research clients.